{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Parkinson+Disease+Psychosis&page=2",
    "query": {
      "condition": "Parkinson Disease Psychosis",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Parkinson+Disease+Psychosis&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-11T09:19:02.295Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00095810",
      "title": "Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Parkinson's Disease",
        "Psychoses"
      ],
      "interventions": [
        {
          "name": "aripiprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2003-07",
      "completion_date": "2004-09",
      "has_results": false,
      "last_update_posted_date": "2013-11-08",
      "last_synced_at": "2026-06-11T09:19:02.295Z",
      "location_count": 1,
      "location_summary": "Albany, New York",
      "locations": [
        {
          "city": "Albany",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00095810"
    },
    {
      "nct_id": "NCT05590637",
      "title": "Comparing Antipsychotic Medications in LBD Over Time",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Parkinson's Disease Psychosis",
        "Dementia With Lewy Bodies"
      ],
      "interventions": [
        {
          "name": "Pimavanserin",
          "type": "DRUG"
        },
        {
          "name": "Quetiapine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 94,
      "start_date": "2022-04-22",
      "completion_date": "2027-02",
      "has_results": false,
      "last_update_posted_date": "2025-09-09",
      "last_synced_at": "2026-06-11T09:19:02.295Z",
      "location_count": 2,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05590637"
    },
    {
      "nct_id": "NCT00009048",
      "title": "EMD 128130 for the Treatment of Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "EMD 128130",
          "type": "DRUG"
        },
        {
          "name": "IV Levodopa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 30,
      "start_date": "2001-01",
      "completion_date": "2003-12",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-06-11T09:19:02.295Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00009048"
    },
    {
      "nct_id": "NCT00360633",
      "title": "Psychiatric and Cognitive Manifestations of Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2006-06",
      "completion_date": "2019-03-28",
      "has_results": false,
      "last_update_posted_date": "2019-05-10",
      "last_synced_at": "2026-06-11T09:19:02.295Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00360633"
    },
    {
      "nct_id": "NCT00087542",
      "title": "Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hallucinations",
        "Psychoses",
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "ACP-103",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ACADIA Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "0 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2004-03",
      "completion_date": "2005-12",
      "has_results": false,
      "last_update_posted_date": "2005-12-07",
      "last_synced_at": "2026-06-11T09:19:02.295Z",
      "location_count": 13,
      "location_summary": "Fountain Valley, California • Sunnyvale, California • Danbury, Connecticut + 10 more",
      "locations": [
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Sunnyvale",
          "state": "California"
        },
        {
          "city": "Danbury",
          "state": "Connecticut"
        },
        {
          "city": "Pompano Beach",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00087542"
    },
    {
      "nct_id": "NCT00043849",
      "title": "Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Dementia",
        "Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "Quetiapine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute on Aging (NIA)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2002-07",
      "completion_date": "2005-06",
      "has_results": false,
      "last_update_posted_date": "2009-12-11",
      "last_synced_at": "2026-06-11T09:19:02.295Z",
      "location_count": 21,
      "location_summary": "Birmingham, Alabama • La Jolla, California • Long Beach, California + 18 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00043849"
    },
    {
      "nct_id": "NCT04373317",
      "title": "Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Parkinson's Disease Psychosis"
      ],
      "interventions": [
        {
          "name": "Pimavanserin",
          "type": "DRUG"
        },
        {
          "name": "Quetiapine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 358,
      "start_date": "2022-10-24",
      "completion_date": "2027-08-24",
      "has_results": false,
      "last_update_posted_date": "2025-08-28",
      "last_synced_at": "2026-06-11T09:19:02.295Z",
      "location_count": 24,
      "location_summary": "Tucson, Arizona • Loma Linda, California • Palo Alto, California + 20 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "West Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04373317"
    },
    {
      "nct_id": "NCT03217110",
      "title": "Cerebellar Stimulation and Cognitive Control",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Schizophrenia",
        "Autism Spectrum Disorder",
        "Bipolar Disorder",
        "Depression",
        "Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "Repetitive Transcranial Magnetic Stimulation (rTMS)",
          "type": "DEVICE"
        },
        {
          "name": "Sham Repetitive Transcranial Magnetic Stimulation (rTMS)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Krystal Parker, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 200,
      "start_date": "2017-11-30",
      "completion_date": "2028-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-19",
      "last_synced_at": "2026-06-11T09:19:02.295Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03217110"
    },
    {
      "nct_id": "NCT03582137",
      "title": "A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "Cannabidiol",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "40 Years to 85 Years"
      },
      "enrollment_count": 74,
      "start_date": "2018-09-05",
      "completion_date": "2022-01-04",
      "has_results": true,
      "last_update_posted_date": "2024-07-23",
      "last_synced_at": "2026-06-11T09:19:02.295Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03582137"
    },
    {
      "nct_id": "NCT05796167",
      "title": "Pimavanserin for Sleep in Parkinson Disease",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "Pimavanserin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "State University of New York - Downstate Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "40 Years to 85 Years"
      },
      "enrollment_count": 0,
      "start_date": "2023-01-27",
      "completion_date": "2024-06-24",
      "has_results": false,
      "last_update_posted_date": "2024-12-20",
      "last_synced_at": "2026-06-11T09:19:02.295Z",
      "location_count": 1,
      "location_summary": "Brooklyn, New York",
      "locations": [
        {
          "city": "Brooklyn",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05796167"
    }
  ]
}